Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
Curis (NASDAQ: CRIS), a biotechnology company developing emavusertib (CA-4948), has scheduled its first quarter 2025 financial results announcement for May 6, 2025, at 8:00 a.m. ET.
The company will host a conference call and webcast at 8:30 a.m. ET on the same day. Investors can participate through:
- U.S. dial-in: (800)-836-8184
- International dial-in: (646)-357-8785
- Live audio webcast: Available on the Curis website's events & presentations section
Emavusertib, their key drug candidate, is an oral small molecule IRAK4 inhibitor. A replay of the conference call will be accessible at www.curis.com.
Curis (NASDAQ: CRIS), un'azienda biotecnologica che sviluppa emavusertib (CA-4948), ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 6 maggio 2025 alle 8:00 ET.
La società terrà una conference call e una webcast alle 8:30 ET dello stesso giorno. Gli investitori potranno partecipare tramite:
- Numero USA: (800)-836-8184
- Numero internazionale: (646)-357-8785
- Webcast audio in diretta: disponibile nella sezione eventi e presentazioni del sito web di Curis
Emavusertib, il loro principale candidato farmaco, è un inibitore orale a piccola molecola di IRAK4. La registrazione della conference call sarà disponibile su www.curis.com.
Curis (NASDAQ: CRIS), una compañía biotecnológica que desarrolla emavusertib (CA-4948), ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 6 de mayo de 2025 a las 8:00 a.m. ET.
La empresa realizará una llamada conferencia y una transmisión en vivo a las 8:30 a.m. ET del mismo día. Los inversores podrán participar a través de:
- Línea telefónica en EE.UU.: (800)-836-8184
- Línea internacional: (646)-357-8785
- Transmisión de audio en vivo: disponible en la sección de eventos y presentaciones del sitio web de Curis
Emavusertib, su principal candidato a medicamento, es un inhibidor oral de pequeñas moléculas de IRAK4. La repetición de la llamada conferencia estará disponible en www.curis.com.
Curis (NASDAQ: CRIS)는 emavusertib (CA-4948)을 개발하는 생명공학 회사로, 2025년 1분기 재무실적 발표를 2025년 5월 6일 오전 8시(ET)에 예정하고 있습니다.
회사는 같은 날 오전 8시 30분(ET)에 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다. 투자자들은 다음을 통해 참여할 수 있습니다:
- 미국 전화 접속: (800)-836-8184
- 국제 전화 접속: (646)-357-8785
- 라이브 오디오 웹캐스트: Curis 웹사이트의 이벤트 및 프레젠테이션 섹션에서 이용 가능
Emavusertib는 주요 약물 후보로, 경구용 소분자 IRAK4 억제제입니다. 컨퍼런스 콜 녹음은 www.curis.com에서 다시 들을 수 있습니다.
Curis (NASDAQ : CRIS), une société de biotechnologie développant emavusertib (CA-4948), a prévu l'annonce de ses résultats financiers du premier trimestre 2025 le 6 mai 2025 à 8h00 ET.
La société organisera une conférence téléphonique et une webdiffusion à 8h30 ET le même jour. Les investisseurs pourront y participer via :
- Numéro d'appel aux États-Unis : (800)-836-8184
- Numéro d'appel international : (646)-357-8785
- Webdiffusion audio en direct : disponible dans la section événements et présentations du site web de Curis
Emavusertib, leur principal candidat-médicament, est un inhibiteur oral de petite molécule ciblant IRAK4. Le replay de la conférence téléphonique sera accessible sur www.curis.com.
Curis (NASDAQ: CRIS), ein Biotechnologieunternehmen, das emavusertib (CA-4948) entwickelt, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 6. Mai 2025 um 8:00 Uhr ET geplant.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten. Investoren können teilnehmen über:
- US-Einwahlnummer: (800)-836-8184
- Internationale Einwahlnummer: (646)-357-8785
- Live-Audio-Webcast: Verfügbar im Bereich Veranstaltungen & Präsentationen auf der Curis-Website
Emavusertib, ihr Hauptmedikamentenkandidat, ist ein oral einzunehmender IRAK4-Inhibitor in Form eines kleinen Moleküls. Eine Aufzeichnung der Telefonkonferenz ist unter www.curis.com verfügbar.
- Curis maintains its NASDAQ listing status (CRIS)
- Company continues development of emavusertib, a key IRAK4 inhibitor drug candidate
- No preliminary financial results provided ahead of the earnings call
- Focus on single drug candidate (emavusertib) suggests limited pipeline diversity
Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can be accessed here or from the events & presentations section of the Curis website. A replay of the conference call will be available at www.curis.com.
About Curis, Inc.
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently being evaluated in the Phase 1/2 TakeAim Lymphoma study (CA-4948-101) in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study (CA-4948-102) in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), and as a frontline combination therapy with venetoclax and azacitidine in patents with AML (CA-4948-104). Emavusertib has received Orphan Drug Designation from the
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-report-first-quarter-2025-financial-and-operating-results-and-host-conference-call-and-webcast-on-may-6-2025-302441183.html
SOURCE Curis, Inc.
FAQ
When will Curis (CRIS) release Q1 2025 earnings?
How can investors join Curis (CRIS) Q1 2025 earnings call?
What is Curis (CRIS) main drug development focus?
Where can I find the replay of Curis (CRIS) Q1 2025 earnings call?
What time is Curis (CRIS) Q1 2025 earnings webcast?
